A Dual-Engine SmellTech Architecture: Ainos at the Edge, ScentAI Scaling AI Intelligence
HOUSTON, TX / ACCESS Newswire / January 2, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today released a statement from Chairman, President and Chief Executive Officer Eddy Tsai, outlining the Company’s long-term platform strategy to digitize smell as a native data language for artificial intelligence, its execution priorities for 2026, and the complementary roles of Ainos and its wholly owned AI software subsidiary, ScentAI Inc. (“ScentAI”), within the SmellTech platform – AI Nose.
Ainos is executing a disciplined, long-term strategy to transform smell from a sensory signal into a structured data language that artificial intelligence systems can understand, learn from, and scale. While AI has successfully converted text, images, and sound into computable tokens, smell remains one of the last major human senses not yet systematically digitized. We believe this represents a structurally significant opportunity in the evolution of AI.
Layered SmellTech Platform Architecture
AI Nose, our SmellTech platform, is designed as a layered and tightly integrated architecture to support scalability, data consistency, and long-term platform durability. Ainos is operating at the edge of the physical world, designing, manufacturing, and deploying its AI Nose sensing hardware. Ainos maintains control over sensor design, firmware, calibration, manufacturing processes, quality assurance, and global certifications to ensure that scent data generated across deployments is reliable, repeatable, and suitable for large-scale AI training.
Rationale for the Dual-Engine Platform Design
Ainos is adopting a dual-engine platform architecture based on long-term design considerations rather than organizational or short-term operational factors. Ainos believes that combining sensing, data generation, and AI intelligence within a single operating structure could constrain scalability and long-term value creation. By separating the sensing layer from the intelligence layer, the platform is designed to preserve strategic flexibility, governance clarity, and scalability as deployments expand.
Structural Separation Between Ainos and ScentAI
Within the SmellTech platform, Ainos focuses exclusively on sensing hardware, physical deployment, and data generation, while ScentAI focuses on AI models, data abstraction, and intelligence delivery. The two entities will not compete at the product or customer level. Instead, they will operate as complementary layers within a unified platform architecture, reducing role ambiguity and long-term operational friction.
Smell Language Model (SLM)
ScentAI is positioned to develop the Smell Language Model (SLM), the core AI system of the SmellTech platform. SLM is designed to classify, contextualize, and enable cross-environment learning of scent data in a structured, trainable format. Through SLM, we expect scent to become an AI-native data asset that can be scaled and monetized through enterprise APIs, SaaS offerings, and model licensing, while Ainos retains ownership of its core datasets and AI models.
2026 Execution Priorities
In 2026, Ainos is committed to driving scaled deployment, with an initial focus on advanced semiconductor manufacturing and robotic applications. These environments demand high sensing precision, reliability, and continuous data generation, making them well-suited for accelerating data accumulation and AI model training. We view these applications as a strong starting point in our expansion to the industrial market, with the AI Nose platform positioned to extend well beyond these initial markets as deployment scales.
Long-Term Platform Value and Data Flywheel
As AI Nose deployments expand, the volume and diversity of scent data increase, driving continuous improvement of the Smell Language Model. This feedback loop between sensing, data accumulation, and model evolution supports the development of recurring, intelligence-driven revenue streams over time, while Ainos maintains control over the sensing layer that anchors the platform.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of “AI” and “Nose,” is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Investor Relations Contact
Feifei Shen
Email: [email protected]
SOURCE: Ainos, Inc.
